دورية أكاديمية
أعرض في EDS

Acute promyelocytic leukemia derived extracellular vesicles conserve PML-RARα transcript from storage-inflicted degradation: a stable diagnosis tool in APL patients.

التفاصيل البيبلوغرافية
العنوان: Acute promyelocytic leukemia derived extracellular vesicles conserve PML-RARα transcript from storage-inflicted degradation: a stable diagnosis tool in APL patients.
المؤلفون: Barzegar M; Laboratory Hematology and Blood Banking, School of Allied Medical Science, Shahid Beheshti University of Medical Sciences, Darband St, Qods Sq, Tehran, Iran., Farsani MA; Laboratory Hematology and Blood Banking, School of Allied Medical Science, Shahid Beheshti University of Medical Sciences, Darband St, Qods Sq, Tehran, Iran.; HSCT Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran., Rafiee M; Laboratory Hematology and Blood Banking, School of Allied Medical Science, Shahid Beheshti University of Medical Sciences, Darband St, Qods Sq, Tehran, Iran., Amiri V; Laboratory Hematology and Blood Banking, School of Allied Medical Science, Shahid Beheshti University of Medical Sciences, Darband St, Qods Sq, Tehran, Iran., Parkhihdeh S; HSCT Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran., Rad F; Department of Hematology and Blood Transfusion, School of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran.; Cellular and Molecular Research Center, Yasuj University of Medical Sciences, Yasuj, Iran., Mohammadi MH; Laboratory Hematology and Blood Banking, School of Allied Medical Science, Shahid Beheshti University of Medical Sciences, Darband St, Qods Sq, Tehran, Iran. Drmohammadi@sbmu.ac.ir.; HSCT Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Drmohammadi@sbmu.ac.ir.
المصدر: Annals of hematology [Ann Hematol] 2021 Sep; Vol. 100 (9), pp. 2241-2252. Date of Electronic Publication: 2021 Jul 08.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9107334 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0584 (Electronic) Linking ISSN: 09395555 NLM ISO Abbreviation: Ann Hematol Subsets: MEDLINE
أسماء مطبوعة: Publication: Berlin : Springer Verlag
Original Publication: Berlin ; New York : Springer International, c1991-
مواضيع طبية MeSH: Extracellular Vesicles/*genetics , Leukemia, Promyelocytic, Acute/*diagnosis , Oncogene Proteins, Fusion/*genetics , Promyelocytic Leukemia Protein/*genetics , Retinoic Acid Receptor alpha/*genetics, Adult ; Aged ; Cell Line, Tumor ; Female ; Gene Dosage ; Humans ; Leukemia, Promyelocytic, Acute/genetics ; Male ; Middle Aged ; Neoplasm, Residual/diagnosis ; Neoplasm, Residual/genetics
مستخلص: The early death, which is more common in acute promyelocytic leukemia (APL) patients rather than other types of acute myelocytic leukemia (AML) highlights the importance of appropriate diagnostic method for early detection of this disease. The low sensitivity of the conventional methods, low tumor burden in some patients, and the need for bone marrow sampling are some of the diagnostic challenges on the way of proper detection of APL. Given these, we aimed to compare the efficacy of extracellular vesicles (EVs), as a diagnostic tool, with the existing methods. RT-PCR, qPCR, and flow cytometry were applied on EVs and their corresponding associated cellular component collected from 18 APL new cases, 23 patients with minimal residual disease (MRD), and NB4 cell line. RT-PCR results were positive in both cellular and vesicular components of all new cases, NB4 cells, and EVs in contrary to MRD cases. Normalized copy numbers (NCN) of PML-RARα were 5100 and 3950 for cell and EVs, respectively (p < 0.05). There was a significant difference in the NCN of PML-RARα between cells and EVs in BM samples. Investigating the effect of storage at room temperature revealed that PML-RARα level was retained near to the baseline level in EVs, but there was a significant reduction in its copy number in the cellular component during 7 days. Taken together, given to the acceptable stability, EVs could be introduced as a non-invasive liquid biopsy that alongside existing methods could remarkably change the paradigm of APL diagnostic approaches.
(© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
References: Bally C, Fadlallah J, Leverger G, Bertrand Y, Robert A, Baruchel A, Guerci A, Recher C, Raffoux E, Thomas X (2012) Outcome of acute promyelocytic leukemia (APL) in children and adolescents: an analysis in two consecutive trials of the European APL Group. J Clin Oncol 30(14):1641–1646. (PMID: 2247316210.1200/JCO.2011.38.4560)
Rodriguez-Rodriguez S, Demichelis-Gómez R, Diaz-Huizar MJ, Guerrero-Torres L, Pomerantz A, del Pilar Ortiz-Vilchis M, Aguayo A (2017) Cost-effectiveness of the regimen proposed by the international consortium on acute promyelocyticleukemia in the treatment of newly diagnosed patients with acute promyelocytic leukemia. Am Soc Hematology.
Fenaux P, Tallman MS, Estey EH, Löwenberg B, Naoe T, Lengfelder E, Döhner H, Burnett AK, Chen SJ, Mathews V (2019) Management of acute promyelocytic leukemia: Updated recommendations from an expert panel of the European LeukemiaNet.
Grimwade D, Jovanovic JV, Hills RK, Nugent EA, Patel Y, Flora R, Diverio D, Jones K, Aslett H, Batson E (2009) Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol 27(22):3650–3658. (PMID: 1950616110.1200/JCO.2008.20.1533)
Hokland P, Ommen HB (2011) Towards individualized follow-up in adult acute myeloid leukemia in remission. Blood 117(9):2577–2584. (PMID: 2109767310.1182/blood-2010-09-303685)
Tobal K, Moore H, Macheta M, Yin JL (2001) Monitoring minimal residual disease and predicting relapse in APL by quantitating PML-RARα transcripts with a sensitive competitive RT-PCR method. Leukemia 15(7):1060. (PMID: 1145597410.1038/sj.leu.2402170)
Wintrobe MM (2008) Wintrobe’s clinical hematology, vol 1. Lippincott Williams & Wilkins.
Marrugo-Ramírez J, Mir M, Samitier J (2018) Blood-based cancer biomarkers in liquid biopsy: a promising non-invasive alternative to tissue biopsy. Int J Mol Sci 19(10):2877. (PMID: 621336010.3390/ijms19102877)
Sasso L, Hosamuddin H, Emanueli C (2017) Extracellular vesicles at the cross-line between basic science and clinical needs. Microcirculation 24(1):e12333. (PMID: 10.1111/micc.12333)
van Niel G, D’Angelo G, Raposo G (2018) Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol 19(4):213. (PMID: 2933979810.1038/nrm.2017.125)
Zhang W, Xia W, Lv Z, Xin Y, Ni C, Yang L (2017) Liquid biopsy for cancer: circulating tumor cells, circulating free DNA or exosomes? Cell Physiol Biochem 41(2):755–768. (PMID: 2821488710.1159/000458736)
Kahlert C, Melo SA, Protopopov A, Tang J, Seth S, Koch M, Zhang J, Weitz J, Chin L, Futreal A (2014) Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer. J Biol Chem 289(7):3869–3875. (PMID: 24398677392425610.1074/jbc.C113.532267)
Caivano A, Laurenzana I, De Luca L, La Rocca F, Simeon V, Trino S, D’Auria F, Traficante A, Maietti M, Izzo T (2015) High serum levels of extracellular vesicles expressing malignancy-related markers are released in patients with various types of hematological neoplastic disorders. Tumor Biology 36(12):9739–9752. (PMID: 2615680110.1007/s13277-015-3741-3)
Yang C, Yang H, Liu J, Zhu L, Yu S, Zhang X (1815) Gao L (2019) Focus on exosomes: novel pathogenic components of leukemia. American journal of cancer research 9(8):1815.
Kunz F, Kontopoulou E, Reinhardt K, Soldierer M, Strachan S, Reinhardt D, Thakur BK (2019) Detection of AML-specific mutations in pediatric patient plasma using extracellular vesicle–derived RNA. Ann Hematol 98(3):595–603. (PMID: 3067381310.1007/s00277-019-03608-y)
Kontopoulou E, Strachan S, Reinhardt K, Kunz F, Walter C, Walkenfort B, Jastrow H, Hasenberg M, Giebel B, von Neuhoff N (2020) Evaluation of dsDNA from extracellular vesicles (EVs) in pediatric AML diagnostics. Ann Hematol 1–17.
Cai J, Han Y, Ren H, Chen C, He D, Zhou L, Eisner GM, Asico LD, Jose PA, Zeng C (2013) Extracellular vesicle-mediated transfer of donor genomic DNA to recipient cells is a novel mechanism for genetic influence between cells. J Mol Cell Biol 5(4):227–238. (PMID: 23580760373341810.1093/jmcb/mjt011)
Szczepanski MJ, Szajnik M, Welsh A, Whiteside TL, Boyiadzis M (2011) Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-β1. Haematologica 96(9):1302–1309. (PMID: 21606166316610010.3324/haematol.2010.039743)
Boyiadzis M, Whiteside TL (2015) Information transfer by exosomes: a new frontier in hematologic malignancies. Blood Rev 29(5):281–290. (PMID: 2568674910.1016/j.blre.2015.01.004)
Sharifi H, Shafiee A, Molavi G, Razi E, Mousavi N, Sarvizadeh M, Taghizadeh M (2019) Leukemia-derived exosomes: bringing oncogenic signals to blood cells. J Cell Biochem 120(10):16307–16315. (PMID: 3112765610.1002/jcb.29018)
Li Y, Zhao J, Yu S, Wang Z, He X, Su Y, Guo T, Sheng H, Chen J, Zheng Q (2019) Extracellular vesicles long RNA sequencing reveals abundant mRNA, circRNA, and lncRNA in Human blood as potential biomarkers for cancer diagnosis. Clin Chem 65(6):798–808. (PMID: 3091441010.1373/clinchem.2018.301291)
Peng M, Xie Y, Li X, Qian Y, Tu X, Yao X, Cheng F, Xu F, Kong D, He B (2019) Resectable lung lesions malignancy assessment and cancer detection by ultra-deep sequencing of targeted gene mutations in plasma cell-free DNA. J Med Genet 56(10):647–653. (PMID: 3098198710.1136/jmedgenet-2018-105825)
Théry C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, Antoniou A, Arab T, Archer F, Atkin-Smith GK (2018) Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles 7(1):1535750. (PMID: 30637094632235210.1080/20013078.2018.1535750)
Pospichalova V, Svoboda J, Dave Z, Kotrbova A, Kaiser K, Klemova D, Ilkovics L, Hampl A, Crha I, Jandakova E (2015) Simplified protocol for flow cytometry analysis of fluorescently labeled exosomes and microvesicles using dedicated flow cytometer. J Extracell Vesicles 4(1):25530. (PMID: 2583322410.3402/jev.v4.25530)
Van Dongen J, Macintyre E, Gabert J, Delabesse E, Rossi V, Saglio G, Gottardi E, Rambaldi A, Dotti G (1901) Griesinger F (1999) Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Leukemia 13(12):1901. (PMID: 10.1038/sj.leu.2401592)
Cassinat B, Zassadowski F, Balitrand N, Barbey C, Rain J, Fenaux P, Degos L, Vidaud M, Chomienne C (2000) Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t (15; 17) translocation using real-time RT-PCR. Leukemia 14(2):324. (PMID: 1067375210.1038/sj.leu.2401652)
Ghaffari S, Rostami S, Bashash D, Alimoghaddam K, Ghavamzadeh A (2006) Real-time PCR analysis of PML-RARα in newly diagnosed acute promyelocytic leukaemia patients treated with arsenic trioxide as a front-line therapy. Ann Oncol 17(10):1553–1559. (PMID: 1683185310.1093/annonc/mdl150)
Santamaría C, Chillón MC, Fernández C, Martín-Jiménez P, Balanzategui A, Sanz RG, San Miguel JF, González M-G (2007) Using quantification of the PML-RARα transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia. Haematologica 92(3):315–322. (PMID: 1733918010.3324/haematol.10734)
Beillard E, Pallisgaard N, Van der Velden V, Bi W, Dee R, van der Schoot E, Delabesse E, Macintyre E, Gottardi E, Saglio G (2003) Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)–a Europe against cancer program. Leukemia 17(12):2474. (PMID: 1456212410.1038/sj.leu.2403136)
Biccler JL, Østgård LSG, Severinsen MT, Marcher CW, Møller P, Schöllkopf C, Friis LS, Bøgsted M, Jakobsen LH, El-Galaly TC (2018) Evolution of relative survival for acute promyelocytic leukemia patients alive at landmark time-points: a population-based study. Leukemia:1.
Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, Faderl S, O’Brien S, Wierda W, Pierce S (2017) Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood 129(10):1275–1283. (PMID: 28003274541329710.1182/blood-2016-09-736686)
Hong C-S, Muller L, Whiteside TL, Boyiadzis M (2014) Plasma exosomes as markers of therapeutic response in patients with acute myeloid leukemia. Front Immunol 5:160. (PMID: 24782865398959410.3389/fimmu.2014.00160)
Hong CS, Muller L, Boyiadzis M, Whiteside TL (2014) Isolation and characterization of CD34+ blast-derived exosomes in acute myeloid leukemia. PloS one 9(8):e103310. (PMID: 25093329412236410.1371/journal.pone.0103310)
Kucharzewska P, Belting M (2013) Emerging roles of extracellular vesicles in the adaptive response of tumour cells to microenvironmental stress. Journal of Extracellular Vesicles 2(1):20304. (PMID: 10.3402/jev.v2i0.20304)
Lv L-H, Wan Y-L, Lin Y, Zhang W, Yang M, Li G-L, Lin H-M, Shang C-Z, Chen Y-J, Min J (2012) Anticancer drugs cause release of exosomes with heat shock proteins from human hepatocellular carcinoma cells that elicit effective natural killer cell antitumor responses in vitro. J Biol Chem 287(19):15874–15885. (PMID: 22396543334609210.1074/jbc.M112.340588)
Fang Y, Garnier D, Lee TH, D’Asti E, Montermini L, Meehan B, Rak J (2016) PML–RARa modulates the vascular signature of extracellular vesicles released by acute promyelocytic leukemia cells. Angiogenesis 19(1):25–38. (PMID: 2637463210.1007/s10456-015-9486-1)
Kang K-W, Jung J-H, Hur W, Park J, Shin H, Choi B, Jeong H, Kim DS, Yu ES, Lee SR (2018) The Potential of exosomes derived from chronic myelogenous leukaemia cells as a biomarker. Anticancer Res 38(7):3935–3942. (PMID: 2997051510.21873/anticanres.12679)
Schuurhuis G, Heuser M, Freeman S, Béné M, Buccisano F, Cloos J, Grimwade D, Haferlach T, Hills R, Hourigan C (2018) Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.
Milani G, Lana T, Bresolin S, Aveic S, Pastò A, Frasson C, Te Kronnie G (2017) Expression profiling of circulating microvesicles reveals intercellular transmission of oncogenic pathways. Mol Cancer Res 15(6):683–695. (PMID: 2820250410.1158/1541-7786.MCR-16-0307)
Ghavamzadeh A, Alimoghaddam K, Rostami S, Ghaffari SH, Jahani M, Iravani M, Mousavi SA, Bahar B, Jalili M (2011) Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J Clin Oncol 29(20):2753–2757. (PMID: 2164661510.1200/JCO.2010.32.2107)
Grimwade D, Coco FL (2002) Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia. Leukemia 16(10):1959–1973. (PMID: 1235734710.1038/sj.leu.2402721)
Boddu P, Jorgensen J, Kantarjian H, Borthakur G, Kadia T, Daver N, Alvarado Y, Pemmaraju N, Bose P, Naqvi K (2018) Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse. Leukemia 32(1):241–244. (PMID: 2891963410.1038/leu.2017.285)
van der Velden VH, Boeckx N, Gonzalez M, Malec M, Barbany G, Lion T, Gottardi E, Pallisgaard N, Beillard E, Hop W (2004) Differential stability of control gene and fusion gene transcripts over time may hamper accurate quantification of minimal residual disease–a study within the Europe Against Cancer Program. Leukemia 18(4):884–886. (PMID: 1496102910.1038/sj.leu.2403309)
Opitz L, Salinas-Riester G, Grade M, Jung K, Jo P, Emons G, Ghadimi BM, Beißbarth T, Gaedcke J (2010) Impact of RNA degradation on gene expression profiling. BMC Med Genomics 3(1):36. (PMID: 20696062292747410.1186/1755-8794-3-36)
Prezeau N, Silvy M, Gabert J, Picard C (2006) Assessment of a new RNA stabilizing reagent (tempus blood RNA) for minimal residual disease in onco-hematology using the EAC protocol. Leuk Res 30(5):569–574. (PMID: 1620988610.1016/j.leukres.2005.08.027)
Ge Q, Zhou Y, Lu J, Bai Y, Xie X, Lu Z (2014) miRNA in plasma exosome is stable under different storage conditions. Molecules 19(2):1568–1575. (PMID: 24473213627196810.3390/molecules19021568)
Kalra H, Adda CG, Liem M, Ang CS, Mechler A, Simpson RJ, Hulett MD, Mathivanan S (2013) Comparative proteomics evaluation of plasma exosome isolation techniques and assessment of the stability of exosomes in normal human blood plasma. Proteomics 13(22):3354–3364. (PMID: 2411544710.1002/pmic.201300282)
معلومات مُعتمدة: 15919 Shahid Beheshti University of Medical Sciences
فهرسة مساهمة: Keywords: Acute promyelocytic leukemia; Extracellular vesicle; Liquid biopsy; Normal copy number
المشرفين على المادة: 0 (Oncogene Proteins, Fusion)
0 (Promyelocytic Leukemia Protein)
0 (RARA protein, human)
0 (Retinoic Acid Receptor alpha)
0 (promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein)
143220-95-5 (PML protein, human)
تواريخ الأحداث: Date Created: 20210708 Date Completed: 20210820 Latest Revision: 20240131
رمز التحديث: 20240201
DOI: 10.1007/s00277-021-04579-9
PMID: 34236496
قاعدة البيانات: MEDLINE
الوصف
تدمد:1432-0584
DOI:10.1007/s00277-021-04579-9